Antibiotic trials point to new ways of tackling dyskinesia in Parkinson's

Direct clinical trials testing immune calming drugs specifically for dyskinesia are still in their infancy. However, a small preliminary human study led by a Brazilian research group gave eight people with dyskinesia a daily dose of the common antibiotic doxycycline for twelve weeks. The participants saw a meaningful drop in their involuntary movements and enjoyed more hours of smooth symptom control without any worsening of their stiffness or slowness. Another small trial found that clearing out gut bacteria and inflammation with targeted treatments also calmed dyskinesia for a few weeks. Even amantadine, the main medication currently prescribed for dyskinesia, is now understood to work partly through its quiet anti inflammatory talents. Meanwhile, a new clinical trial testing a specialised anti inflammatory drug called AVI 009 is preparing to launch with dyskinesia as its primary target. These clinical breakthroughs are the focus of an October 2026 review in the Journal of Neural Transmission led by Bruno Lopes Santos Lobato and Elaine Del Bel. For decades, the involuntary twisting and fidgeting movements caused by long term levodopa use were explained purely as a chemical wiring problem. As the brain loses its natural dopamine storage capacity, taking a levodopa tablet sends a sudden wave of chemical crashing into the striatum, the movement hub of Parkinson's. Neighbouring serotonin cells try to help by converting levodopa into dopamine, but because they lack a safety valve, they dump it all out at once. This creates wild chemical swings that make receiving brain cells overly sensitive, triggering involuntary movements when the dose peaks. The Brazilian team gathered years of evidence proving that chronic brain inflammation lowers the threshold for this chaotic rewiring. When levodopa hits the brain in sudden waves, the resident immune cells of Parkinson's, known as microglia and astrocytes, become agitated. Instead of keeping the peace, they pump out inflammatory signals and excess nitric oxide gas. At the same time, tiny blood vessels in the movement centre sprout leaky new branches, letting levodopa rush into the brain even faster and amplifying the chemical rollercoaster. Laboratory tests show just how strongly this inflammatory loop drives dyskinesia. Blocking excess nitric oxide in animal models calmed both the immune cells and the involuntary movements. Doxycycline and cannabidiol, widely known as CBD, also proved effective in lab tests by soothing agitated immune cells, protecting cellular power plants, and smoothing out movement control. Clues from human samples tell the exact same story. Blood and spinal fluid tests from people living with dyskinesia reveal higher levels of nitric oxide byproducts, altered fats, and immune system alarm bells compared to people who take levodopa without developing involuntary movements. Brain scans and tissue studies further confirm damaged cellular energy factories and unusual blood flow in the movement centres of people with dyskinesia. Genetics also helps explain why some people develop these movements much earlier than others. Studies of thousands of people living with Parkinson's found that variations in genes like GBA1 and LRRK2, which govern how cells handle waste, fats, and inflammation, make a person much more susceptible to dyskinesia. By looking beyond dopamine and treating this combination of localized brain inflammation, cellular energy stress, and genetic risk, researchers are opening a practical new way to keep levodopa working smoothly for the long haul.